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Pyrroloquinoline quinone (PQQ) influences energy-related metabolism and neurologic functions in animals. The mechanism of action involves interactions
with cell signaling pathways and mitochondrial function. However, little is known about the response to PQQ in humans. Using a crossover study design, 10
subjects (5 females, 5 males) ingested PQQ added to a fruit-flavored drink in two separate studies. In study 1, PQQ was given in a single dose (0.2 mg PQQ/kg).
Multiple measurements of plasma and urine PQQ levels and changes in antioxidant potential [based on total peroxyl radical-trapping potential and thiobarbituric
acid reactive product (TBAR) assays] were made throughout the period of 48 h. In study 2, PQQ was administered as a daily dose (0.3 mg PQQ/kg). After 76 h,
measurements included indices of inflammation [plasma C-reactive protein, interleukin (IL)-6 levels], standard clinical indices (e.g., cholesterol, glucose, high-
density lipoprotein, low-density lipoprotein, triglycerides, etc.) and 1H-nuclear magnetic resonance estimates of urinary metabolites related in part to oxidative
metabolism. The standard clinical indices were normal and not altered by PQQ supplementation. However, dietary PQQ exposure (Study 1) resulted in apparent
changes in antioxidant potential based on malonaldehyde-related TBAR assessments. In Study 2, PQQ supplementation resulted in significant decreases in the
levels of plasma C-reactive protein, IL-6 and urinary methylated amines such as trimethylamine N-oxide, and changes in urinary metabolites consistent with
enhanced mitochondria-related functions. The data are among the first to link systemic effects of PQQ in animals to corresponding effects in humans.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.Keywords: PQQ; Mitochondria; Inflammation; Biofactor; nutrient; Human metabolism1. Introduction
Pyrroloquinoline quinone (PQQ) acts as a novel growth factor in
both plants [1] and animals [2,3]. The mechanism of action in animal
models and cultured cells involves the activation or expression of
factors, such as peroxisome proliferator-activated receptor alpha;
cAMP response element-binding; nuclear respiratory factors 1 and 2;
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Open access under CC BY-NlC-SA licactivated receptor-γ coactivator 1-alpha [4,5]. Each of these tran-
scription factors and coactivators plays a central role in the regulation
of cellular energy metabolism (e.g., promotion of β-oxidation) and
mitochondrial biogenesis [4–10] and are related to the remodeling of
muscle tissue to a fiber-type composition that is metabolically more
oxidative and less glycolytic [11,12]. In addition, genes important to
cellular stress (e.g., thioredoxin), cell signaling (Janus kinase-, MAPK-
and STAT-related pathways) and nutrient transport are affected [5],
which suggests that PQQ may act initially through cell surface
cytokine and/or growth factor receptors [11,12] or by influencing the
phosphorylation of key components [13,14].
When added to nutritionally complete, semipurified diets devoid of
PQQ, as little as 300 μg PQQ per kg diet improves reproduction and
enhances neonatal rates of growth in rats and mice compared to the
response fromdiets devoid of PQQ [5–10]. PQQ exposure (3mg PQQ/kg
body weight) also results in the protection of cardiac and neural tissue
following experimentally induced ischemia in rodent models [15–17].
However, no reports are available regarding whether PQQ evokes
similar physiological responses in humans. Humans consume from
0.1 to 1.0 mg PQQ and its derivatives per day based on available food
compositional data [18–20]. Animal and human tissues contain from
1 to 3 ng of nonderivatized PQQ per gram tissue ormilliter of fluid, i.e.,ense.
Fig. 1. Dietary PQQ, serum, and urine PQQ levels. PQQ serum concentrations increased directly in response to dietary intake, and the daily excretion of PQQ in urine was related to both
the serum levels of PQQ and the daily PQQ intake. At each dose of PQQ, approximately 0.1% of the parent compound (nonderivatized PQQ) was recovered in urine based on a glucose
dehydrogenase assay specific for PQQ (see text). Values with differing superscripts are significant at Pb.01 (ANOVA using a Tukey correction).
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PQQ appears sufficient to maintain nanomolar concentrations in
animal tissues, measured as the parent compound [18]. Organisms
common to the gut do not produce PQQ in amounts that are easily
determined [21]. Moreover, the levels of PQQ in animal tissues are
responsive to changes in diet [5–10].
The reduced form of PQQ is a potent antioxidant and capable of
catalyzing continuous and repeated oxidation and reduction reactions
in chemical assays [13,22–27]. For example, PQQ is 100–1000 times
more efficient than other quinone biofactors in assays designed to
assess redox cycling [22]. Other quinone biofactors also tend to either
self-oxidize or condense into inactive forms. In contrast, PQQ is
relatively stable and does not easily polymerize. It is also noteworthy
that there may have been a constant exposure to PQQ-like
compounds throughout biological evolution based on the observa-
tions that stellar dust contains PQQ-like compounds [28].
Given such findings, the studies reported herein were designed to
assess whether PQQ promotes biological responses in humans
consistent to those reported in experimental animals. Data are
presented that PQQ does improve antioxidant potential and alters
markers of inflammation, such as C-reactive protein (CRP). In
addition, indirect estimates of oxidative metabolism, based on
changes in urinarymetabolites, indicate that PQQ ingestion influences
mitochondrial function.2. Materials and methods
2.1. Human studies
Subjects (5 female and 5male) were recruited (mean age: 28.1 years; range: 23–33
years, female; 21–34 years, male). All participants were employed or students at the
University of California, Davis. Subjects were asked to abstain from alcohol, analgesics
and nutritional supplements, but otherwise consume their normal diets.
To assess potential dosages for subsequent clinical studies, the relationship between
the dietary intake of PQQ and changes in PQQ plasma and urinary concentrations was
first examined in a preliminary study. Following basal estimates, PQQ was administered
at 0.075 mg PQQ/kg body weight per day for 7 days, followed by 0.15 mg PQQ/kg body
weight per day for 7 days and 0.3 mg PQQ/kg body weight per day for 7 days. At the end
of each of these periods, plasma PQQ and urinary PQQ were measured.Next, two separate studies were conducted using a crossover design. For each
study, baseline plasma and urine samples were obtained, i.e., prior to PQQ
supplementation. PQQ was administered in ~6–8 fluid ounces (~180–240 ml) of an
orange drink. For assays using plasma, 18 ml of venous blood was drawn into
Vacutainer tubes containing EDTA or sodium heparin (Becton Dickinson, Franklin
Lakes, NJ, USA). Plasma was separated by low-speed centrifugation (1500×g at 4°C for
10 min) and stored at −80°C until analysis. For assays using urine, 100-ml samples
were obtained in acid-washed containers at each time point and frozen immediately.
In Study 1, PQQ was administered in a single dose at 0.2 mg PQQ/kg body weight.
Plasma and urine samples were then obtained at 0 (baseline), 2, 4, 8, 24 or 48 h
following PQQ supplementation. Measurements included assessments of PQQ in
plasma and urine and plasma antioxidant potential plus standard clinical indices [e.g.,
aspartate aminotransferase (AAT), cholesterol, glucose, high- (HDL) and low-density
lipoprotein (LDL) levels, uric acid, triglycerides (TG), uric acid and protein; see
descriptions that follow].
In study 2, PQQ was administered daily at 0.3 mg PQQ/kg body weight for 3 days.
Blood samples were obtained by venipuncture at baseline (0 h) and the morning of day
4, i.e., following 72 h of daily PQQ supplementation. Indices related to PQQ status,
inflammation [CRP, interleukin (IL)-6 and matrix metalloproteinase (MMP)-9] and
urinary metabolites reflecting oxidative metabolism (e.g., various amino acid-,
carbohydrate-, or fatty acid-derived products) were measured.
All studies were reviewed and approved by the Institutional Review Board
(Federal-wide assurance 00004557) under the auspices of IRB 200816307, UC Davis.
2.2. PQQ
PQQ was measured in serum and urine using a glucose-dehydrogenase-based
assay system [29–31]. PQQ was extracted from tissue and plasma as described by
Suzuki et al. [31]. Recoveries based on samples (serum samples spiked with PQQ) were
routinely 85% or greater.
2.3. Plasma antioxidant activity
Antioxidant activity was based on measurements of plasma thiobarbituric acid
reactive products (TBARS) and the intensity of luminol-induced chemiluminescence by
radicals derived from the thermolysis of 2,2'-azo-bis[2-amidinopropane], as a measure
of total peroxyl radical-trapping potential (TRAP). For the TBARS assay, 100 μl of
plasma was mixed with 200 μl of 3% sodium dodecyl sulfate, 800 μl of 0.1 mol/L HCl,
100 μl 10% (wt/v) phosphotungstic acid and 400 μl of 0.7% (wt/vol) 2-thiobarbituric
acid and incubated (95°C for 30 min). Samples were cooled on ice andmixed with 1 ml
of n-butanol. After centrifugation (1800×g, 10 min, 4°C), a 200-μl aliquot of the n-
butanol phase was separated and analyzed spectrofluorometrically (excitation=515
nm and emission=555 nm) using a plate reader attachment (Perkin-Elmer Cetus,
Norwalk, CT, USA). TBARS are expressed as malondialdehyde equivalents [32,33].
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chemiluminescence produced by a mixture of 3 ml of 5.4 mg/ml 2,2'-azo-bis
[amidinopropane] in 0.1 mmol/L phosphate-buffered saline (PBS), pH 7.4 (GIBCO
BRL, Life Technologies, Grand Island, NY, USA), and 10 μl of 1 mg/ml luminol [34]. The
lag time was measured that proceeds the increase in luminol-induced chemilumines-
cence derived from the thermolysis of 2,2'-azo-bis[2-amidinopropane]. The lag time is
proportional to antioxidant capacity. A reference lag time was obtained by using
(10 μM Trolox in 1× PBS) of 6-hydroxy-2,5,7,8-tetramethoxychroman-2-carboxylic
acid (Trolox; Aldrich Chemical Co., Milwaukee, WI, USA).
2.4. Inflammation-related assays
CRP was measured using a commercial assay kit (ALPCO, Keewaydin Drive, Salem,
NH, USA; 03079Kit 30-9710S) following the protocol providedwith the kit (http://www.
alpco.com/pdfs/30/30-9710s.pdf). For IL-6, an optimized enzyme-linked immunosorbent
assay (ELISA) kit specific for human IL-6 was used (Thermo Fisher Scientific, Rockford, IL,
USA; 61105 Kit EH2IL6) based on the colorimetric enzyme-linked quantification of
human IL-6 in serum. The assay standard was calibrated to an international reference
standard. The sensitivity was less than 2 pg IL-6/ml. MMP-9 (associated with tissue
remodeling at sites of inflammation) was also estimated using an ELISA assay (Invitrogen
MMP-9 Immunoassay Kit, Catalog #KHC3062/KHC3061; Invitrogen, Camarillo, CA, USA)
as an additional estimate of inflammatory response [35,36].
2.5. Other clinical parameters
Aspartate amino acid transferase, cholesterol, creatinine, glucose, HDL, LDL, TG,
uric acid and total protein were measured in plasma using a COBAS c111 analyzer
(Roche Diagnostics, Indianapolis, IN, USA) using methods and reagents supplied by
the manufacturer.
2.6. Urinary metabolites and nuclear magnetic resonance (NMR)
NMR spectra were acquired as previously described [37,38] using a Bruker Avance
600-mHz NMR spectrometer equipped with a sample jet autosampler using the NOESY-Fig. 2. Levels of PQQ in serum and urine and serum TBAR in response to a single oral supplement
the levels of PQQweremeasured in serum and urine. PQQ peaked in serum at ~2–3 h. The rise a
(B). For panels (A) and (B), values with differing superscripts are significantly different from ea
were also observed in response to the PQQ supplementation (C). The initial value (equiva
malondialdehyde) at P~.06 based on a paired t test. The gradual decrease in malondialdehyde
for change in TBAR values and peak serum PQQ values (D) was R=0.74 (Pb.5).presaturation pulse sequence at 25°C. Samples were prepared for NMR spectroscopy by
centrifuging to remove particulate matter followed by the addition of 65 μl of internal
standard containing 5 mM 3-(trimethylsilyl)-1-propanesulfonic acid-d6 and 0.2% NaN3
in 99.8% D2O to 0.585ml of urine supernatant. The pH of each sample was adjusted to 6.8
±0.1. Spectrawere acquiredwith a spectral width of 12 ppm, amixing time of 100ms, 32
transients, 8 dummy scans and an acquisition time of 2.5 s. Water suppression was
accomplished through application of a low-power pulse during the prescan delay (2.5 s)
andmixing time (100ms). Once acquired, all spectrawere zero-filled to 128k data points,
Fourier transformed with a 0.5-Hz line broadening, phased and baseline corrected using
NMR Suite 6.1 Processor (Chenomx Inc., Edmonton, Canada). Identification and
quantification of metabolites were accomplished using the 600-MHz library from the
Chenomx NMR Suite 6.1 Profiler, which uses the concentration of a known reference
signal (DSS) to determine the concentration of compounds [37,38].
2.7. Statistical analysis
A Student’s t test (paired) was used for direct comparisons. For multiple
comparisons, an analysis of variance (ANOVA) employing a Tukey or Dunnett post
hoc correction was performed.
3. Results
3.1. Dietary PQQ, serum PQQ levels, urinary excretion of PQQ and
changes in antioxidant potential
To establish an oral dose of PQQ that would result in a 5–10-fold
increase in the plasma levels of PQQ, the relationship between the
PQQ intake, corresponding plasma levels and urinary excretion was
assessed. A close relationship was observed between intake, the
concentration of PQQ in serum and the amounts of PQQ excreted in
urine (Fig. 1). At each dose (0 to 0.3 mg/kg/day), ~0.1% of the PQQof PQQ. A single dose of PQQ [0.2mg PQQ/kg bodyweight (BW)]was administered, and
nd clearance of PQQ paralleled the changes in urine. Values aremeans (n=10)±1 S.E.M.
ch other at Pb.01 (ANOVA using a Tukey post hoc correction). Changes in plasma TBARS
lent to 0.79 nmol/ml as malondialdehyde) differs from the final value (0.7 nmol/ml
over time appeared linear (R=0.95) and significant (Pb.01). The correlation coefficient
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concentrations of nonderivatized PQQ increased in response to
dietary intake (R2N0.9, Pb.05), and the daily excretion of PQQ in
urine was directly related to serum levels (R2N0.9, Pb.05).
Following a single dose of PQQ (0.2 mg PQQ/kg body weight;
Study 1), levels of PQQ peaked in serum at ~2 h (Fig. 2A). The rise and
clearance of PQQ in serum paralleled the changes in urine (Fig. 2B).
We also assessed if the changes in plasma PQQ concentrations
following oral administration would result in measurable and
corresponding changes in reactive oxidant products. Changes in
TBARS, which measure malondialdehyde generated from lipid
hydroperoxides, and TRAP values were chosen as indices. Although
no significant changes were observed in the TRAP values, there was a
slight but significant decrease in TBAR values over the time course of
Study 1 (Fig. 2C). Further, individual values expressed as ΔTBAR
values (0 hTBARvalue minus 48 hTBARvalue) were correlated with plasma
Cmax values for PQQ (Fig. 2D, Pb.05).
3.2. CRP, IL-6 and MMP-9
The levels of CRP, MMP-9 and the cytokine IL-6 are given in Fig. 3A–
C. The serum CRP level was reduced for each of the 10 subjects in
response to oral administration of PQQ (Pb.05). The serum CRP
concentrations were also positively associated with IL-6 levels
(Fig. 3D). The positive relationship between IL-6 and CRP was taken
in part as validation that PQQ was capable of attenuating an
inflammatory response [39–42]. There was no change inMMP-9 levels.
3.3. Clinical indices
To determine whether a brief exposure to PQQ influences standard
clinical indices (Studies 1 and 2), estimates of total cholesterol, creatine,Fig. 3. PQQ, plasma CRP, IL-6, andMMP-9 levels. Plasma CRP and IL-6 levels were decreased in e
baseline values. The solid bars represent values following PQQ supplementation at 0.3 mg/kg B
at Pb.05. The changes in levels for male and female subjects and the total group of subjects are
related roles in the inflammatory response. The positive relationship between IL-6 and Δ log CR
inflammatory response involving CRP and IL-6 (see Discussion). No changes were observed iglucose, LDL, HDL, TG, uric acid, total protein, and AAT isozyme activity
[35,36]weremeasured at 48 h after a single dose of PQQ (Study 1) or 72
h after a continuous daily dose of PQQ. As indicated in Table 1, the
various values were all within normal ranges [43].
3.4. Urinary metabolites related to mitochondrial function
In Figs. 4–6 and Table 2, the relative changes in concentrations of
urinary metabolites are presented (Study 2; response to 0.3 mg PQQ/
day × 3 days). Significant differences were observed for urinary
lactate (P~.03) following PQQ supplementation (Fig. 4). Pyruvic acid
was also reduced (P~.07), and the initial ratio of lactate to pyruvate
was reduced from 4.5±0.5 to 3.6±0.35. Although no significant
changes were observed for other citric acid cycle intermediates, when
their respective urinary concentrations were summed (citrate
+isoaconitate+2-ketoglutarate+succinate), the values following
PQQ supplementation were reduced from baseline by ~15%, with a
reduction in the urinary fumarate level of 18% (Pb.07). These data
were taken to suggest that PQQ might influence mitochondrial
efficiency, assuming the relative reduction in urinary concentrations
reflects increased oxidation and flux of citric acid cycle intermediates
via mitochondria [44–46].
Fig. 5 shows data for methylated amine products, which are
derived largely from gut microbial metabolism [47–51]. Methylated
amine compounds can be eventually metabolized to trimethylamine
N-oxide (TMAO) primarily in the liver by flavin-containing mono-
oxygenases (derived from the FMO3 gene) [50]. Changes in TMAO are
of particular interest because of their use as urinary markers in
atherosclerosis [47–50], diabetes [51] and perturbations in energy
metabolism in animal models [52]. We previously observed that PQQ-
deprived rats have lower levels of expression of FMO3 based on geneach of the 10 subjects in response to oral administration of PQQ. Open bars represent the
W for each of 3 days. Corresponding bars with differing letter designation are significant
shown in panels (A) to (C). Both IL-6 and CRP levels were measured because they have
P values (D) was taken as an internal validation that PQQ was capable of attenuating an
n MMP-9.
Table 1
Effect of PQQ supplementation on serum clinical indices
Study 1a
Indices Day 0 Post 48 h
Aspartate transaminase (U/L) 29±1.1 24±1.1
Cholesterol (mg/L) 175±6 177±6
Creatine (mg/dl) 0.8±0.06 0.8±0.05
Glucose (mg/L) 89±6 94±6
HDL (mg/L) 52±2 53±3
LDL (mg/L) 110±9 109±9
TG (mg/L) 89±11 91±12
Uric acid (mg/dl) 4.7±0.5 4.5±0.6
Total protein (g/L) 7.2±0.2 7.3±0.3
Study 2a
Indices Day 0 Post 72 h
Aspartate transaminase (U/L) 29±1.1 24±1.1
Cholesterol (mg/L) 169±7 183±9
Creatine (mg/dl) 0.8±0.07 0.8±0.08
Glucose (mg/L) 90±3 85±4
HDL (mg/L) 51±3 54±2
LDL (mg/L) 102±11 112±13
TG (mg/L) 81±14 94±12
Uric acid (mg/L) 4.9±0.4 4.5±0.3
Total protein (g/L) 7.1±0.2 7.2±0.2
a PQQ was supplemented at 0.2 mg/kg/day (Study 1) and at 0.3 mg/kg/day (Study
2). Values are means±1 S.E.M.
Fig. 4. PQQ and relative changes in urinary TCA cycle metabolites. In Study 2, differences were o
values (μmol/L) were 45±6 (PQQ+) vs. 35±4 (PQQ−) for pyruvate and 195±20 (PQQ+) vs.
0.35 and was reduced to 3.6±0.35 following PQQ supplementation (P~.1). Values are means±
at Pb.05. The inclusion of an asterisk (*) indicates a P value ofN.05 but b0.1. Regarding the oth
citrate, 3570±666 [baseline (BL)] vs. 3278±512 [PQQ supplemented (PS)]; cis- plus trans-aco
succinate, 93±18 (BL) vs. 78±18 PS; and fumarate, 5.1±0.5 (BL) vs. 4.3±0.4 (PS).
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Fig. 5 suggest that short-term PQQ exposure in humans may also
result in reduced TMAO production.
In Table 2, values for urinary glucose, selected amino acid, and
ketone-related metabolites are summarized. Attention was paid to
amino acids that are metabolized predominantly in resting muscle;
for example, leucine, isoleucine, asparagine, aspartate, valine and
glutamate. These amino acids provide the amino groups and
ammonia required for synthesis of glutamine and alanine [53]. In
addition, serine was examined because of its important role in
pyruvate metabolism, and 4-hydroxyphenylacetate and 4-hydroxy-
phenyllactate were included because their respective urinary levels
decrease when β-oxidation is enhanced [46].
Regarding specific amino acids, although changes in the amounts
of most of the amino acid-related metabolites that were detected by
1H-NMR (approximately 30 total) were not influenced following PQQ
supplementation, collectively, there was a significant reduction of
~15% in the total amount of amino acids excreted (baseline vs. PQQ
supplementation, Pb.01). Further, significant differences or strong
trends were observed for serine, isoleucine, asparagine and aspartic
acid, four of the six amino acids that are metabolized predominantly
in resting muscle (Table 2). Significant differences were also observed
in 4-hydroxyphenylacetate plus 4-hydroxyphenyllactate urinary
levels (baseline vs. PQQ supplementation, Pb.05).bserved for lactate (Pb.03) and pyruvate (P~.07) after 3 days of PQQ exposure. Themean
121±15 (PQQ−) for lactate. The initial ratio of lactate to pyruvate was 4.5±0.5 to 3.6±
1 standard mean error. Corresponding values with differing superscripts are significant
er TCA cycle intermediates that are shown, the mean values (μmol/L) were as follows:
nitate, 506±112 (BL) vs. 385±53 (PS); 2-ketoglutarate, 202±28 (BL) vs. 192±53 (PS);
Fig. 5. PQQ and urinary methylated amines. Important methylated amines are shown. Amajor end product of methylated aminemetabolism is TMAO, which is produced in the liver by
the action of monooxygenase (isozyme 3). Values are means±1 standard mean error. Corresponding values with differing superscripts are significant at Pb.05.
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relationships, such as the relationship between glutamine and
glutamate and creatinine and the methylhistidines, were examined.
Significant correlation coefficients were observed when the amounts
of glutamate excreted were plotted vs. glutamine excreted (R=0.94,
Pb.001, Fig. 6A) and the amounts of creatinine vs. methylhistidines
were plotted, particularly 3-N-methylhistidine (R=0.95, Pb.001,
Fig. 6B and C). Other changes that suggested perturbations in
nitrogen metabolism were decreases in urea excretion (Fig. 6 D,
Pb.01).
In contrast, as a measure of purine-related metabolites, no
differences were observed for hypoxanthine (baseline vs. following
PQQ supplementation, 115±17 [SEM] vs. 123±35 μmol/L, respec-
tively) or uracil (baseline vs. following PQQ supplementation, 102±9
vs. 102±13 μmol/L, respectively). The amounts of urinary myo-
inositol were also not changed (baseline vs. following PQQ supple-
mentation, 325±96 vs. 263±73 μmol/L, respectively), nor were the
levels of hippuric acid (baseline vs. following PQQ supplementation,
2097±1195 vs. 2037±2020 μmol/L, respectively), which is often used
as a marker for changes in the microbiome [55].
4. Discussion
The data reported are among the first to link systemic effects of
PQQ in animals to related or corresponding effects in humans. For
example, PQQ influences the immune response in mice through
mechanisms that involve changes in interleukin levels [9]. In humans,
PQQ appears to promote anti-inflammatory potential, which could be
related to changes in plasma CRP and IL-6 levels [39–42]. Reductions
of both CRP and IL-6 following PQQ ingestion were observed,
important because CRP expression is dependent on IL-6. IL-6 helpsto coregulate B cell differentiation, plasmacytogenesis and the acute
phase reactions [55,56], leading to the production and release of CRP
into circulation. Normal levels of CRP in healthy human serum are
usually substantially lower than 10 mg/L [40]; accordingly, it is
noteworthy that PQQ supplementation reduced further CRP levels by
~45%. Moreover, although subtle, the changes in plasma TBARS values
(~ 0.2% decrease in relative TBAR values/h following supplementa-
tion, Pb.05) and its association with changes in plasma PQQ levels (in
the 6–12-nM range) suggest that PQQ has potential as an antioxidant.
For comparison, Rein et al. [57] have reported that the consumption
~560 mg of procyanidins in the form of 80 g of dark chocolate results
in the appearance of 200–300 nM of epicatechin in plasma with an
accompanying decrease (25%–35%) in TBAR levels in as few as 2 h.
The data were also consistent with features associated with
mitochondrial-related oxidative metabolism [2–8,10–14]. A poten-
tially important finding was the relative decreases in mitochondrial-
related intermediates and metabolites in urine following PQQ
exposure. These changes are consistent with increased mitochondrial
efficiency and in keeping with other observations wherein 1H-NMR
data of urinary metabolite profiles have been used to assess
differences in metabolic efficiency or disease relationships when
mitochondrial function is important [45–52].
We previously have shown that, in animal models, dietary PQQ
exposure improves various indices related to oxidative metabolism,
for example, parameters that reflect changes in the rates of β-
oxidation [6,7], mitochondrial-related amino acid metabolism [10]
and the amounts of mtDNA [4–10]. Similar changes have been
reported when streptozotocin-treated diabetic rats are compared to
rats with normal glycemic control [45] or rats fed diets containing
0.2% or more resveratrol vs. a standard control diet [58,59]. For
example, the relative levels of urinary and serum pyruvate, various
Fig. 6. PQQ and indices of muscle protein retention. The relationships for glutamate vs. glutamine (A), creatinine vs. 1-N-methylhistidine (B), creatinine vs. 3-N-methylhistidine (C),
and urinary creatinine and urea levels (D) are shown. Baseline values are indicated by open circles, and values following PQQ supplementation are indicated by closed circles. It was
expected that glutamine and glutamate would be related. The correlation coefficient between glutamate and glutamine prior to PQQ supplementation was R=0.94 (Pb.001). The value
for R for the combined data was 0.77 (Pb.05) (A). As shown in panels (B) and (C), the relative concentrations of creatinine, 1-N-methylhistidine and 3-N-methylhistidine were also
correlated. The combined correlation coefficients between creatinine and 1-N-methylhistidine (B) and between creatinine and 3-N-methylhistidine (C) were R=0.55 (Pb.05) and R=
0.95 (Pb.001), respectively. The levels of urinary creatinine and urea are given in panel (D). There was a significant reduction in the amounts of urea excreted (Pb.05).
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tocin-diabetic rats compared to rats in which oxidative metabolism is
not compromised [45]. With regard to humans, subjects with
compromised β-oxidation or type II diabetics also have elevated
values for plasma and/or urinary pyruvate and various citric acid cycle
intermediates and, particularly in diabetes, elevated TMAO urinary
levels [51], metabolites that are influenced by PQQ supplementation.
Bennett et al. [60] have recently reported that TMAO levels are
strongly associated with atherosclerosis. Increased TMAO levels are
associated with inhibition of the reverse cholesterol transport
pathway [60]. Consequently, it may be of clinical significance and
potential importance that PQQ supplementation reduces the levels of
urinary TMAO.Table 2
PQQ and mitochondrial-related metabolites, urinary glucose and ketone-related productsa
Metabolite Initial values
(μM/L)
Urinary amino acids
Serine 551±98
Asparagine 146±18
Aspartic acid 143±75
Total 289±40
Isoleucine 27±4.0
4-Hydroxyphenylacetate 192±51.6
4-Hydroxyphenyllactate 37±10.7
Total 229±56
Urinary glucose and ketone-related products
Glucose 340±37
3-Hydroxybutyrate 121±38
Acetate 94±16
a PQQ was supplemented at 0.3 mg/kg/day (Study 2). Values are means±1 S.E.M.Of the six amino acids that are metabolized predominately by
mitochondria in resting muscle (leucine, isoleucine, valine, aspara-
gine, aspartate and glutamate) [61], the levels of urinary isoleucine
and asparagine/aspartate were significantly reduced following PQQ
supplementation. Further, given the overall decrease in amino acid
excretion, it would be expected that such phenomena may result in
some degree of nitrogen retention. In this regard, Walsh et al. [62] has
examined phytochemical intake and its influence on urinary
metabolic profiles. A low-phytochemical diet (no fruits or vegetables)
was compared to a phytochemical-enriched diet using the subject’s
conventional diet as a control. The consumption of a high level of
polyphenolic compounds compared to lower levels of exposure for 2
days was characterized by decreased excretion of creatinine, creatine,Values following PQQ supplementation
(μM/L)
P value
356±63 .08
99±10 .03
95±33 .08
194±16 .03
12±2.1 .045
137±49.3 .03
20±4.3 .12
157±51 .04
328±46 .87
83±14 .32
75±10 .24
2083C.B. Harris et al. / Journal of Nutritional Biochemistry 24 (2013) 2076–2084TMAO, and 1- and 3-methylhistidine, which is consistent with our
observations following supplementationwith PQQ. Clearly, more data
are needed to identify other components responsible for N retention
in addition to skeletal muscle. The microbiome is one possibility,
although a direct effect on microbial populations was not clear. For
example, the levels of methylamines were variable, and hippuric acid,
which is sometimes used as a marker for changes in the microbiome
[54], did not appear to be influenced by PQQ supplementation.
Moreover, urinary choline concentrations, an important source of
microbially derived methylamines, were not significantly different
after supplementation with PQQ. This is an area to be addressed in
future studies.
In summary, PQQ influences a wide range of systemic res-
ponses ranging from the stimulation of reproductive performance
and neonatal growth in animal models fed highly refined diets
to modulation in mitochondrial content and β-oxidation potential
at dietary levels of exposure that are one to two orders of
magnitudes below those required for biofactors, such as resvera-
trol (cf. [59] and references cited). Further, when the responses to
PQQ are compared to other vitamins with redox cycling activity
(e.g., ascorbic acid), the actions are often the opposite of those
observed for PQQ, i.e., a reduction or no change in mitochondrial
biogenesis or function [63,64]. The data herein support the hypothesis
that human subjects respond rapidly to PQQ supplementation with
changes inurinarymetabolites consistentwith enhancedmitochondria-
related functions.References
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